

PRODUCT INFORMATION

Clone ID	DMC267
Target	TNFSF11
Synonyms	CD254; hRANKL2; ODF; OPGL; OPTB2; RANKL; sOdf; TNLG6B; TRANCE
Host Species	Rabbit
Description	Biotinylated Anti-TNFSF11 antibody(DMC267); IgG1 Chimeric mAb
Delivery	2-3 weeks
Uniprot ID	O14788
IgG type	Rabbit/Human Fc chimeric IgG1
Clonality	Monoclonal
Reactivity	Human
Applications	Flow Cyt
Recommended Dilutions	Flow Cyt 1:100
Purification	Purified from cell culture supernatant by affinity chromatography
Formulation & Reconstitution	Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
Storage & Shipping	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
Background	This gene encodes a member of the tumor necrosis factor (TNF) cytokine family which is a ligand for osteoprotegerin and functions as a key factor for osteoclast differentiation and activation. This protein was shown to be a dendritic cell survival factor and is involved in the regulation of T cell-dependent immune response. T cell activation was reported to induce expression of this gene and lead to an increase of osteoclastogenesis and bone loss. This protein was shown to activate antiapoptotic kinase AKT:PKB through a signaling complex involving SRC kinase and tumor necrosis factor receptor-associated factor (TRAF) 6; which indicated this protein may have a role in the regulation of cell apoptosis. Targeted disruption of the related gene in mice led to severe osteopetrosis and a lack of osteoclasts. The deficient mice exhibited defects in early differentiation of T and B lymphocytes; and failed to form lobulo-alveolar mammary structures during pregnancy. Two alternatively spliced transcript variants have been found.
Usage	Research use only
Conjugate	Biotinylated
DIMA Disclaimer	All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.



DIMABIO CONFIDENTIAL

